Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market by Novo Nordisk.
- Korte W (9 July 2014). "Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?". J Blood Med. 5: 107–13. doi:10.2147/JBM.S35395. PMC 4096448. PMID 25031548.
- Mozaffari S, Nikfar S, Abdollahi M (July 2015). "Inflammatory bowel disease therapies discontinued between 2009 and 2014". Expert Opin Investig Drugs. 24 (7): 949–56. doi:10.1517/13543784.2015.1035432. PMID 25861835. S2CID 26104155. CNDO-210 and Catridecacog were discontinued due to safety concerns and lack of efficacy, respectively.
External links
- "Blood-coagulation factor XIII". Drug Information Portal. U.S. National Library of Medicine.
References
NHS New Drugs Online Report for catridecacog Archived 2015-07-03 at the Wayback Machine Page accessed July 2, 2015 http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5744 ↩
Catridecacog: First drug to treat rare genetic blood clotting disorder. The Pharmacist February 01, 2014 http://www.pharmacist.com/catridecacog-first-drug-treat-rare-genetic-blood-clotting-disorder ↩
NHS New Drugs Online Report for catridecacog Archived 2015-07-03 at the Wayback Machine Page accessed July 2, 2015 http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5744 ↩